Advances in drug therapies for cytomegalovirus in transplantation: a focus on maribavir and letermovir

References

• Bruminhent J, Watcharananan SP. Cytomegalovirus infection in non-HIV patients: a return of the monster. J Infect Dis Antimicrob Agents. 2018;35(2):111–114.
   Google Scholar
• Razonable RR, Humar A. Cytomegalovirus in solid-organ transplant recipients—guidelines of the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13512.
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018 June;102(6):900–931. PubMed PMID: 29596116; eng.
   PubMed Web of Science ®Google Scholar
• El Helou G, Razonable RR. Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation. Expert Opin Drug Saf. 2019 Nov;18(11):1017–1030. PubMed PMID: 31478398.
   PubMed Web of Science ®Google Scholar
• Razonable RR. Drug-resistant cytomegalovirus: clinical implications of specific mutations. Curr Opin Organ Transplant. 2018 Aug;23(4):388–394. PubMed PMID: 29794552.
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013 Sep 26;369(13):1227–1236. PubMed PMID: 24066743; eng.
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Chemaly RF, et al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019 Feb;25(2):369–381. PubMed PMID: 30292744; eng.
   PubMed Web of Science ®Google Scholar
• de la Cámara R. CMV in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;8(1):e2016031. PubMed PMID: 27413524; PubMed Central PMCID: PMCPMC4928522. eng.
   PubMedGoogle Scholar
• Meesing A, Razonable RR. Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation. Expert Rev Clin Pharmacol. 2018 Aug;11(8):773–788. PubMed PMID: 30009675.
   PubMed Web of Science ®Google Scholar
• Meesing A, Razonable RR. New developments in the management of cytomegalovirus infection after transplantation. Drugs. 2018 July;78(11):1085–1103. PubMed PMID: 29961185.
   PubMed Web of Science ®Google Scholar
• Meesing A, Abraham RS, Razonable RR. Clinical correlation of cytomegalovirus infection with CMV-specific CD8+ T-cell immune competence score and lymphocyte subsets in solid organ transplant recipients. Transplantation. 2019 Apr;103(4):832–838. PubMed PMID: 30086091.
   PubMed Web of Science ®Google Scholar
• Acosta E, Bowlin T, Brooks J, et al. Advances in the development of therapeutics for cytomegalovirus infections. J Infect Dis. 2020 Mar 5;221(Supplement_1):S32–S44. PubMed PMID: 32134483; PubMed Central PMCID: PMCPMC7057787.
   PubMedGoogle Scholar
• Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007 Sep;7(9):2106–2113. PubMed PMID: 17640310; eng.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Chou S, Einsele H, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clinl Infect Dis. 2019 Apr 8;68(8):1420–1426. PubMed PMID: 30137245; eng.
   PubMed Web of Science ®Google Scholar
• Bruminhent J, Rotjanapan P, Watcharananan SP. Epidemiology and outcome of ganciclovir-resistant cytomegalovirus infection after solid organ transplantation: a single transplant center experience in Thailand. Transplant Proc. 2017 June;49(5):1048–1052. PubMed PMID: 28583524.
   PubMed Web of Science ®Google Scholar
• Chou S. Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. Antiviral Res. 2020 Apr;176:104711. PubMed PMID: 31940472; PubMed Central PMCID: PMCPMC7080590.
   PubMed Web of Science ®Google Scholar
• El Helou G, Razonable RR. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review. Infect Drug Resist. 2019;12:1481–1491. PubMed PMID: 31239725; PubMed Central PMCID: PMCPMC6556539.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014 May 8;370(19):1781–1789. PubMed PMID: 24806159; eng.
   PubMed Web of Science ®Google Scholar
• Piret J, Boivin G. Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance. Antiviral Res. 2019 Mar;163:91–105. PubMed PMID: 30690043.
   PubMed Web of Science ®Google Scholar
• Kropeit D, Scheuenpflug J, Erb-Zohar K, et al. Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment. Br J Clin Pharmacol. 2017 Sep;83(9):1944–1953. PubMed PMID: 28345163; PubMed Central PMCID: PMCPMC5555856. eng.
   PubMed Web of Science ®Google Scholar
• McCrea JB, Macha S, Adedoyin A, et al. Pharmacokinetic drug-drug interactions between letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil. J Clin Pharmacol. 2019 Oct;59(10):1331–1339. PubMed PMID: 30990905.
   PubMed Web of Science ®Google Scholar
• Duong A, Sweet A, Jain R, et al. Clinically significant drug interaction: letermovir and voriconazole. J Antimicrob Chemother. 2020 Mar 1;75(3):775–777. PubMed PMID: 31800049; PubMed Central PMCID: PMCPMC7021092.
   PubMed Web of Science ®Google Scholar
• Maples KT, Maloy M, Devlin S, et al. Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. Bone Marrow Transplant. 2020 Jan 14;55(8):1687–1689. PubMed PMID: 31937928.
   PubMed Web of Science ®Google Scholar
• Kropeit D, von Richter O, Stobernack H-P, et al. Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects. Clin Pharmacol Drug Dev. 2018 [2018 Jan];7(1):9–21. PubMed PMID: 28967706; eng.
   PubMed Web of Science ®Google Scholar
• Razonable RR. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation. Curr Opin Infect Dis. 2018 Aug;31(4):286–291. PubMed PMID: 29746444.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017 Dec 21;377(25):2433–2444. PubMed PMID: 29211658.
   PubMed Web of Science ®Google Scholar
• Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European conference on infections in leukaemia (ECIL 7). Lancet Infect Dis. 2019 Aug;19(8):e260–e272. PubMed PMID: 31153807.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Schmitt M, Marty FM, et al. A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clinl Infect Dis. 2020 Apr 10;70(8):1525–1533. PubMed PMID: 31179485.
   PubMed Web of Science ®Google Scholar
• Anderson A, Raja M, Vazquez N, et al. Clinical “real-world” experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. Clin Transplant. 2020 Apr;3:e13866. PubMed PMID: 32242979.
   Google Scholar
• Sharma P, Gakhar N, MacDonald J, et al. Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant. 2020 Apr;55(4):780–786. PubMed PMID: 31664185.
   PubMed Web of Science ®Google Scholar
• Robin C, Thiebaut A, Alain S, et al. Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate program. Biol Blood Marrow Transplant. 2020 Feb 5;26:978–984. PubMed PMID: 32035273.
   Google Scholar
• Marty FM, Ljungman PT, Chemaly RF, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2019 Dec 28. PubMed PMID: 31883426. DOI:10.1111/ajt.15764
   Web of Science ®Google Scholar
• Stoelben S, Arns W, Renders L, et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transplant Int. 2014 Jan;27(1):77–86. PubMed PMID: 24164420; eng.
   PubMed Web of Science ®Google Scholar
• Aryal S, Katugaha SB, Cochrane A, et al. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. Transpl Infect Dis. 2019 Dec;21(6):e13166. PubMed PMID: 31487755.
   PubMedGoogle Scholar
• Cherrier L, Nasar A, Goodlet KJ, et al. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant. 2018 Dec;18(12):3060–3064. PubMed PMID: 30286286; PubMed Central PMCID: PMCPMC6263820.
   PubMed Web of Science ®Google Scholar
• Phoompoung P, Ferreira VH, Tikkanen J, et al. Letermovir as salvage therapy for cytomegalovirus infection in transplant recipients. Transplantation. 2020 Feb;104(2):404–409. PubMed PMID: 32000236.
   PubMed Web of Science ®Google Scholar
• Jo H, Kwon DE, Han SH, et al. De novo genotypic heterogeneity in the UL56 region in cytomegalovirus-infected tissues: implications for primary letermovir resistance. J Infect Dis. 2020 Apr 7;221(9):1480–1487. PubMed PMID: 31802131.
   PubMed Web of Science ®Google Scholar
• Douglas CM, Barnard R, Holder D, et al. Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients. J Infect Dis. 2020 Mar 16;221(7):1117–1126. PubMed PMID: 31781762; PubMed Central PMCID: PMCPMC7075417.
   PubMed Web of Science ®Google Scholar
• Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019 Sep 19;381(12):1136–1147. PubMed PMID: 31532960; eng.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008 June 1;111(11):5403–5410. PubMed PMID: 18285548; PubMed Central PMCID: PMCPMC5726327.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011 Apr;11(4):284–292. PubMed PMID: 21414843.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012 Nov;12(11):3021–3030. PubMed PMID: 22947426.
   PubMed Web of Science ®Google Scholar
• Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clinl Infect Dis. 2019 Apr 8;68(8):1255–1264. PubMed PMID: 30329038; PubMed Central PMCID: PMCPMC6451997.
   PubMed Web of Science ®Google Scholar
• Chou S, Wu J, Song K, et al. Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. Antiviral Res. 2019 Dec;172:104616. PubMed PMID: 31568799; PubMed Central PMCID: PMCPMC6892599.
   PubMed Web of Science ®Google Scholar